Biotech is back but is it any safer?


After years in the wilderness the few surviving biotech and healthcare funds are talking of a new paradigm and say it it will be different this time

After a two-year slump, biotech is back on top again. And the recent approval of ImClone's experimental cancer drug Erbitux has given the industry another boost and persuaded many hedge fund investors to take another look at the sector, which is populated by a number of big players such as OrbiMed, Deerfield and MPM and is showing signs of spawning a series of new healthcare funds over the coming months with four